Herceptin: latest news - GoINPHARMA
Tuesday, 22 January 2019 - 3:36


Positive opinion by ODAC (FDA) for two biosimilars by Amgen and Mylan

Amgen and Mylan hit a major target as they benefited from FDA’s Oncologic Drugs Advisory Committee (ODAC) positive opinion on the commercialization of two biosimilars – respectively manufactured by each company – to Roche’s cancer drugs Avastin and Herceptin. These…

New details on Samsung BioLogics IPO

Korea-based Samsung Biologics, whose many activities include developing biosimilars and biologic drugs, yesterday announced fresh details on its IPO. Samsung BioLogics plans to place a minimum of 16.5m shares priced at between KW113,000 and KW136,000 apiece, corresponding to $1.7bn to…